Enanta Pharmaceuticals to Participate in Two Investor Conferences in May
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will participate in two investor conferences in May. The JMP Securities Life Sciences Conference fireside chat will be held on May 16 at 9:30 a.m. ET, and the RBC Capital Markets Global Healthcare Conference fireside chat will be held on May 17 at 2:05 p.m. ET. The webcasts will be accessible on Enanta's website, and replays will be available for at least 30 days.
05/09/2023 - 07:00 AM
WATERTOWN, Mass. --(BUSINESS WIRE)--
Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in May:
JMP Securities Life Sciences Conference: Fireside Chat at 9:30 a.m. ET on May 16, 2023
RBC Capital Markets Global Healthcare Conference: Fireside Chat at 2:05 p.m. ET on May 17, 2023
A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com . Replays of the webcasts will be available following the presentations and will be archived for at least 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).
Enanta receives royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S. ) and MAVIRET® (ex-U.S. ) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005465/en/
Media and Investors
jviera@enanta.com
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will participate in the investor conferences in May.
The JMP Securities Life Sciences Conference fireside chat will be held on May 16 at 9:30 a.m. ET.
The RBC Capital Markets Global Healthcare Conference fireside chat will be held on May 17 at 2:05 p.m. ET.
The webcasts can be accessed on Enanta's website.
Yes, replays of the webcasts will be available for at least 30 days.
Enanta Pharmaceuticals Inc
ENTA Rankings
#5339 Ranked by Stock Gains
ENTA Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Watertown
About ENTA
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
